MASSACHUSETTS: Critics Chide State over Cervical Cancer Vaccine Delays

Important note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.

MASSACHUSETTS: Critics Chide State over Cervical Cancer Vaccine Delays

Boston Herald (12.26.06) - Thursday, December 28, 2006
Jessica Fargen

Planned Parenthood says Massachusetts has been slow to cover the cost of Gardasil, which protects against several strands of human papillomavirus (HPV) responsible for 70 percent of US cervical cancer cases. "Massachusetts should be a leader on this and should cover it for all women who want and need to get vaccinated," said Dr. Karen Lifford, medical director at the Planned Parenthood League of Massachusetts.

MassHealth, the state's health insurance for the poor, covers the cost of the vaccine in doctors' offices and hospitals, but it will be another month or more before Gardasil is covered at family planning clinics, according to Paul Jeffrey, MassHealth pharmacy director. He said the rollout is complex but MassHealth wants to pay for Gardasil, adding that it has paid 63 Gardasil claims since August.

Approved by the FDA in August, Gardasil is recommended for females ages 9 to 26. This year, according to the American Cancer Society, about 9,710 women will get cervical cancer and some 3,700 will die from it.

Jennifer Hyde of Westwood-Mansfield Pediatrics said there has been interest in Gardasil. "We were worried parents wouldn't want to talk to their 11-year-olds about having sex, but I think that hasn't really been a problem," she said. "We explain you have to have the vaccine before you've been exposed to the virus. We want to get the girls way before they've had exposure."

According to Gardasil's manufacturer, Merck, more than 39 states offer Gardasil free to females age 18 and younger.
061228
AD062510

Copyright © 2006 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.